Treatment with tDD EC/D improved 10-year BCRFS across all subgroups including according to menopausal status, with an absolute benefit of 2% or more, as well as in luminal (Hazard Ratio [HR] = 0.83, 95% Confidence Interval [CI] 0.65–1.05) and Human Epidermal Growth Factor Receptor 2 (HER2) positive (HR = 0.53, 95% CI 0.30–0.93), but not triple negative breast cancer patients (HR = 1.02, 95% CI 0.66–1.57). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.